These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 12890149

  • 1. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
    Kodityal S, Manhas AH, Udden M, Rice L.
    Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
    [Abstract] [Full Text] [Related]

  • 2. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T, Perry CM.
    Drugs; 2002 Aug; 62(15):2283-314. PubMed ID: 12381232
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
    Koster A, Meyer O, Hausmann H, Kuppe H, Hetzer R, Mertzlufft F.
    J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.
    Lindhoff-Last E, Betz C, Bauersachs R.
    Clin Appl Thromb Hemost; 2001 Oct; 7(4):300-4. PubMed ID: 11697713
    [Abstract] [Full Text] [Related]

  • 9. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.
    Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN, Australian HIT Study Group.
    Thromb Haemost; 2001 Nov; 86(5):1170-5. PubMed ID: 11816702
    [Abstract] [Full Text] [Related]

  • 10. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases.
    Tardy-Poncet B, Wolf M, Lasne D, Bauters A, Ffrench P, Elalamy I, Tardy B.
    Intensive Care Med; 2009 Aug; 35(8):1449-53. PubMed ID: 19350215
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
    Dworschak M, Hiesmayr JM, Lassnigg A.
    Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
    de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, Hart HC, Sixma JJ, Nieuwenhuis HK.
    Ann Intern Med; 1995 Jul 01; 123(1):1-9. PubMed ID: 7539233
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
    Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN.
    Thromb Haemost; 2005 Jan 01; 93(1):63-9. PubMed ID: 15630492
    [Abstract] [Full Text] [Related]

  • 19. The management of heparin-induced thrombocytopenia.
    Keeling D, Davidson S, Watson H, Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology.
    Br J Haematol; 2006 May 01; 133(3):259-69. PubMed ID: 16643427
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.